Abstract
In 2011, the so-called Dubois criteria introduced the use of biomarkers in research (in particular, brain amyloid positron emission tomography imaging and the cerebrospinal fluid levels of tau/fosfo-tau and beta-amyloid 1-42) for the early or preclinical diagnosis of Alzheimer's disease. Even so, we are looking at an increased use of these markers in clinical practice. In the 1960s, Alzheimer's disease was considered a rare form of presenile dementia, but gradually it has been recognized as the prevalent form of old-age dementia. As a consequence, what was once regarded as an inevitable outcome of old age is now recognized as a true disease. Several factors contributed to this paradigm shift, in particular a longer lifespan, new techniques of in vivo study of the central nervous system, and the pressure exerted by the pharmaceutical industry and patient groups. The current lack of disease-modifying therapies and the high incidence of mild cognitive impairment, which is a risk factor for dementia, raise a series of clinical ethical problems ranging from how diagnosis is communicated to how resources are used. This article offers a conceptual scheme through which these issues can be addressed. Copyright - Il Pensiero Scientifico Editore.
| Original language | Italian |
|---|---|
| Pages (from-to) | 295-299 |
| Number of pages | 5 |
| Journal | Recenti Progressi in Medicina |
| Volume | 105 |
| Issue number | 7-8 |
| Publication status | Published - 2014 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Malattia di Alzheimer : La diagnosi tra ricerca, prassi clinica ed etica. / Tarquini, Daniela; Pucci, Eugenio; Gasparini, Maddalena; Zullo, Silvia; Tiraboschi, Pietro; Bonito, Virginio; Defanti, Carlo Alberto.
In: Recenti Progressi in Medicina, Vol. 105, No. 7-8, 2014, p. 295-299.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Malattia di Alzheimer
T2 - La diagnosi tra ricerca, prassi clinica ed etica
AU - Tarquini, Daniela
AU - Pucci, Eugenio
AU - Gasparini, Maddalena
AU - Zullo, Silvia
AU - Tiraboschi, Pietro
AU - Bonito, Virginio
AU - Defanti, Carlo Alberto
PY - 2014
Y1 - 2014
N2 - In 2011, the so-called Dubois criteria introduced the use of biomarkers in research (in particular, brain amyloid positron emission tomography imaging and the cerebrospinal fluid levels of tau/fosfo-tau and beta-amyloid 1-42) for the early or preclinical diagnosis of Alzheimer's disease. Even so, we are looking at an increased use of these markers in clinical practice. In the 1960s, Alzheimer's disease was considered a rare form of presenile dementia, but gradually it has been recognized as the prevalent form of old-age dementia. As a consequence, what was once regarded as an inevitable outcome of old age is now recognized as a true disease. Several factors contributed to this paradigm shift, in particular a longer lifespan, new techniques of in vivo study of the central nervous system, and the pressure exerted by the pharmaceutical industry and patient groups. The current lack of disease-modifying therapies and the high incidence of mild cognitive impairment, which is a risk factor for dementia, raise a series of clinical ethical problems ranging from how diagnosis is communicated to how resources are used. This article offers a conceptual scheme through which these issues can be addressed. Copyright - Il Pensiero Scientifico Editore.
AB - In 2011, the so-called Dubois criteria introduced the use of biomarkers in research (in particular, brain amyloid positron emission tomography imaging and the cerebrospinal fluid levels of tau/fosfo-tau and beta-amyloid 1-42) for the early or preclinical diagnosis of Alzheimer's disease. Even so, we are looking at an increased use of these markers in clinical practice. In the 1960s, Alzheimer's disease was considered a rare form of presenile dementia, but gradually it has been recognized as the prevalent form of old-age dementia. As a consequence, what was once regarded as an inevitable outcome of old age is now recognized as a true disease. Several factors contributed to this paradigm shift, in particular a longer lifespan, new techniques of in vivo study of the central nervous system, and the pressure exerted by the pharmaceutical industry and patient groups. The current lack of disease-modifying therapies and the high incidence of mild cognitive impairment, which is a risk factor for dementia, raise a series of clinical ethical problems ranging from how diagnosis is communicated to how resources are used. This article offers a conceptual scheme through which these issues can be addressed. Copyright - Il Pensiero Scientifico Editore.
KW - Alzheimer's disease
KW - Biomedical research
KW - Clinical ethics
KW - Diagnosis
KW - Mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=84904463241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904463241&partnerID=8YFLogxK
M3 - Articolo
C2 - 25072545
AN - SCOPUS:84904463241
VL - 105
SP - 295
EP - 299
JO - Recenti Progressi in Medicina
JF - Recenti Progressi in Medicina
SN - 0034-1193
IS - 7-8
ER -